Protocol H8H -MC-LAIA 
Bioequi
valence of Lasmiditan Oral Disintegrating Tablet Compared to Current Immediate -
Release Tablet Formulation to Support Treatment of Migraine  
NCT048817
47 
Approval
 Date: 8- Sep-2020 
CONFIDENTIAL Protocol  H8H -MC-LAIA
1Title Page
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators.  It is the property of 
Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical 
investigation of lasmiditan (LY 573144), unless such persons are bound by a confidentiality agreement with Eli Lilly and Company 
or its subsid iaries. 
Note to Regulatory Authorities:   This document may contain protected personal data and/or commercially confidential 
information exempt from public disclosure.  Eli Lilly and Company requests consultation regarding release/redaction prior to any 
public release.  In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not b e 
reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries .
Protocol Title: Bioequivalence of Lasmidi tan Oral  Disintegrating Tablet Compared to Current 
Immediate -Release Tablet Form ulation to Support Treatment of Migraine
Protocol Number: H8H -MC-LAIA
Amendment Number: This is the i nitialprotocol
Compound :Lasmiditan (LY573144)
Study Phase: 1
Short Title: Bioequivalence of 
lasmidi tan oral disintegrating tablet compared to current 
immediate -release tablet f ormulation to support treatm ent of  migraine
Sponsor Name: Eli Lilly  and Com pany
Legal Registered Address: Indianapo lis, Indiana USA 46285
Regulatory Agency Identifier Number(s)
IND: 103420
Approval Date: Protocol Electronically Signed and Approved by Lilly ondate provi ded bel ow.
Approval Date: 08-Sep-2020 GMT
CONFIDENTIAL Protocol  H8H -MC-LAIA
2Medical Monitor Name and Contact Information will be provided separately .
CONFIDENTIAL Protocol  H8H -MC-LAIA
3Table of Content s
1. Protocol Summary ...................................................................................................... 6
1.1. Synopsis ....................................................................................................................... 6
1.2. Schema ......................................................................................................................... 9
1.3. Schedule of Act ivities (SoA) ...................................................................................... 10
2. Introduction .............................................................................................................. 12
2.1. Study  Rati onale.......................................................................................................... 12
2.2. Background ................................................................................................................ 12
2.3. Benefit/Risk Assessment ............................................................................................ 13
3. O bjectives and Endpoints ......................................................................................... 14
4. Study Design ............................................................................................................. 15
4.1. Overall Design ............................................................................................................ 15
4.2. Scientific Rati onale f or Study  Design ......................................................................... 16
4.3. Justification for Dose .................................................................................................. 16
4.4. End of Study  Definit ion.............................................................................................. 16
5. Study Population ...................................................................................................... 17
5.1. Inclusio n Cri teria........................................................................................................ 17
5.2. Exclusio n Cri teria....................................................................................................... 18
5.3. Lifes tyle Considerat ions............................................................................................. 19
5.3.1. Meals and Dietary  Restri ctions................................................................................... 20
5.3.2. Caffeine, Alcoho l, and Tobacco .................................................................................. 20
5.3.3. Activity...................................................................................................................... 20
5.4. Screen Failur es........................................................................................................... 20
6. Study Intervention .................................................................................................... 21
6.1. Study  Intervent ions Administered ............................................................................... 21
6.1.1. Administrati on Details ................................................................................................ 21
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................. 22
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 22
6.4. Study  Intervent ion Compliance ................................................................................... 22
6.5. Concomitant Therapy .................................................................................................23
6.6. Dose Modificat ion...................................................................................................... 23
6.7. Intervention after the End of the Study ........................................................................ 23
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 24
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 24
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. 24
7.2.1. Discontinuati on of  Inadvertent ly Enrolled Participants ............................................... 25
7.3. Lost to Follow -up....................................................................................................... 25
8. Study Assessments and Procedures ......................................................................... 26
8.1. Efficacy Assessments .................................................................................................26
8.2. Safety Assessments .................................................................................................... 26
8.2.1. Physical Examinat ions................................................................................................ 26
8.2.2. Vital Signs.................................................................................................................. 27
CONFIDENTIAL Protocol  H8H -MC-LAIA
48.2.3. Electrocardiograms ..................................................................................................... 27
8.2.4. Clinical Safety  Laboratory  Assessments ..................................................................... 27
8.2.5. Safety Moni toring ....................................................................................................... 28
8.3. Adverse Events and Serious Adverse Events .............................................................. 30
8.3.1. Time Period and Frequency  for Collect ing AE and SAE 
Inform ation................................................................................................................. 30
8.3.2. Method of Detecting AEs and SAEs ........................................................................... 31
8.3.3. Follow-up of  AEs and SAEs ....................................................................................... 31
8.3.4. Regulatory  Reporting Requirements for SAEs ............................................................ 31
8.3.5. Pregnancy ................................................................................................................... 31
8.3.6. Product Complaint s.................................................................................................... 32
8.4. Treatment of Overdose ............................................................................................... 33
8.5. Pharmacokinet ics........................................................................................................ 33
8.5.1. Bioanalysis ................................................................................................................. 33
8.6. Pharmacodynamics ..................................................................................................... 33
8.7. Genet ics..................................................................................................................... 33
8.8. Biomarkers ................................................................................................................. 33
8.9. Immunogenicit y Assessments ..................................................................................... 34
8.10. Health Economics ....................................................................................................... 34
8.11. Product Acceptabilit y and Palatabilit y Assessments .................................................... 34
9. Statistical Considerations ......................................................................................... 35
9.1. Statistical Hypotheses .................................................................................................35
9.2. Sample Si ze Determinat ion......................................................................................... 35
9.3. Popul ations for Analyses ............................................................................................ 35
9.3.1. Study  Parti cipant Disposit ion...................................................................................... 35
9.3.2. Study  Parti cipant Characterist ics................................................................................. 35
9.4. Statistical Analyses ..................................................................................................... 36
9.4.1. General Considerations ............................................................................................... 36
9.4.2. Pharmacokinet ic Analyses .......................................................................................... 36
9.4.3. Safety Analyses .......................................................................................................... 37
9.4.4. Product Acceptabilit y and Palatabilit y Analyses ......................................................... 37
9.5. Interim Analyses ......................................................................................................... 37
9.6. Data Monitoring Committee (DMC) ........................................................................... 37
10. Supporting Documentation and Operational Considerations ................................ 38
10.1. Appendix 1: Regulatory , Ethical , and Study  Oversight 
Considerations ............................................................................................................ 38
10.1.1. Regulatory  and Ethi cal Considerat ions........................................................................ 38
10.1.2. Inform ed Consent Process .......................................................................................... 38
10.1.3. Data Protection ........................................................................................................... 39
10.1.4. Disseminat ion of Clinical Study  Data ......................................................................... 39
10.1.5. Data Qualit y Assurance .............................................................................................. 40
10.1.6. Source Documents ...................................................................................................... 41
10.1.7. Study  and Si te Start and Cl osure ................................................................................. 41
10.1.8. Publicat ion Policy ....................................................................................................... 42
10.2. Appendix 2: Clinical Laboratory  Tests ........................................................................ 43
10.2.1. Blood Sam pling Summary .......................................................................................... 45
CONFIDENTIAL Protocol  H8H -MC-LAIA
510.3. Appendix 3: Adverse Events: Definit ions and Procedures for 
Recording, Evaluat ing, Follow -up, and Reporting ....................................................... 46
10.3.1. Definit ionof AE................................
......................................................................... 46
10.3.2. Definit ion of SAE ....................................................................................................... 47
10.3.3. Recording and Fo llow-up of  AE and/or SAE .............................................................. 48
10.3.4. Reporting of SAEs ...................................................................................................... 49
10.4. Appendix 4: Contraceptive Guidance and Co llection of 
Pregnancy Information ............................................................................................... 51
10.4.1. Definit ions.................................................................................................................. 51
10.4.2. Contraception Guidance .............................................................................................. 51
10.4.3. Contraception Methods ............................................................................................... 52
10.4.4. Collect ion of Pregnancy  Information.......................................................................... 53
10.5. Appendix 5: Genetics .................................................................................................54
10.6. Appendix 6: Liver Safet y: Suggested Actions and Follow -up 
Assessments ............................................................................................................... 55
10.7. Appendix 7: Abbreviat ions......................................................................................... 57
11. References ................................................................................................................. 59
CONFIDENTIAL Protocol  H8H -MC-LAIA
7Overall Design
Screening
All participants will be screened within 28 days prior to enrollment. 
Treatment and Assessment Period
Eligible participants will take part in 3 separate dosing periods. In each period, participants will 
be admitted to the clinical research unit (CRU) on Day  -1 and remain resident in the CRU unt il 
discharge on Day 6. 
There will be a washout period of ≥5 days between the day  of dosing in 1 peri od and the day  of 
dosing in the subsequent period. Days 5 and 6 of Period 1 and 2 may  coincide wi th Days -1 and 
1 of Period 2 and 3, respectively, provided the required washout between lasmiditan doses is 
observed. 
OnDay 1 of Period 1, parti cipants will be equally  randomized to receive a 100 -mg oral dose in 
1of 6 dosing sequences in each of 3 dosing periods. 
Pharmacokinet ic blood sampling and safet y assessments, including vital sign measurements,
physical examinat ions, clinical laboratory  tests, el ectrocardi ograms, and adverse event recording 
will be performed according to the Schedule o f Activit ies.
Follow -up
Day 6 of Period 3 will  be consi dered the final visit of the study . 
Disclosure Statement : Thisis a Phase 1, open -label , randomized, single -dose, 3-way crossover 
study , with 6sequences in healt hy participants.
Number of Participant s:Approximately 48partici pants will be enro lled to ensure that 
36participants, 6 per treatment sequence, complete the study .
Intervention Groups and Duration :Participants will receive single 100-mg dose sof lasmiditan 
in each of 3 dosing periods ,according to 1 of the randomized sequences detailed below.
CONFIDENTIAL Protocol  H8H -MC-LAIA
8Dosing Sequences for Protocol H8H -MC-LAIA
Sequence Period 1 Period 2 Period 3
1 IR (reference) OD without water (test) OD with water (test)
2 IR (reference) OD with water (test) OD without water (test)
3 OD without water (test) OD with water (test) IR (reference)
4 OD without water (test) IR (reference) OD with water (test)
5 OD with water (test) IR (reference) OD without water (test)
6 OD with water (test) OD without water (test) IR (reference)
Abbreviations: IR = immediate release; OD = oral disintegrating.
Screening will occur up to 28 day s prior to enrollment . Each participant will take part in 
3treatm ent peri ods.In each period, participants will be admitted to the CRU on Day  -1 and 
remain resi dent in the CRU unt il discharge on Day 6. At the discret ion of the invest igator, 
participants m ay remain resident in the CRU for the ent irety of the study , i.e., from admissi on to 
the CRU on Day  -1 of Period 1 until discharge from the CRU on Day 6 of Period 3, after all 
assessments have been co mpleted. 
Data Monitoring Committee: No
CONFIDENTIAL Protocol  H8H -MC-LAIA
91.2. Schema

CONFIDENTIAL Protocol  H8H -MC-LAIA
101.3. Schedule of Activities (SoA)
Study Schedule Protocol H8H -MC-LAIA
Screening Dosing Periods 1 to 3 Comments
Procedure-28 to -2 
days prior 
to D1D-1 a D1a D2 D3 D4 D5 a D6a ED
Informed consent X
Admission to CRU XParticipants may remain at the CRU throughout the 
duration of the study, at the discretion of the 
investigator , i.e., admission to CRU in Period 1 only.
Discharge from CRU XParticipants may remain at the CRU throughout the 
duration of the study, at the discretion of the 
investigator , i.e., discharge from CRU in Pe riod 3 only.
Medical history and 
demographicsX
Participant eligibility XConfirm participant eligibility against inclusion and 
exclusion criteria (see Section 5).
Lasmiditan 
administrationXA minimum washout of 5 days between lasmiditan 
doses is required. 
Height X
Weight X
Urine drug screen X XOn D -1, only required if participant is being admitted to 
CRU.
Alcohol breath test X XOn D -1, only required if participant is being admitted to 
CRU.
Pregnancy test X XSerum pregnancy test to be performed at screening. 
Urine pregnancy test to be performed on D -1
(admission to CRU only).
Supine vital signs
(pulse rate, blood 
pressure, and oral 
body temperature)X X P, 1, 2 h 24 h XTime point smay be added for each period, if warranted 
and agreed up on between Lilly and the investigator.
12-lead ECG X P
CONFIDENTIAL Protocol  H8H -MC-LAIA
11Screening Dosing Periods 1 to 3 Comments
Procedure-28 to -2 
days prior 
to D1D-1 a D1a D2 D3 D4 D5 a D6a ED
Clinical laboratory 
testsX X 24 h X See Appendix 2 (Section 10.2) for details. 
Full p hysical 
examinationXAdditional symptom -driven physical examinations may 
be performed at the discretion of the investigator.
Pharmacog enetic   
blood sampleP D1 of Period 1 only.
PK sampling in 
plasma (lasmiditan 
and M8)P, 0.5, 1, 1.5, 
2, 2.5, 3, 4, 
6, 8, 12 h24 h 48 h 72 h 96 h 120 hThe 120 h sample may serve as the D1 predose sample 
for subsequent periods , if participants are remaining 
in-house .
Product acceptability 
and palatability XD1 of dosing p eriodswhen the OD tablet is 
administered either with or without water. Complete 
questionnaire immediately after ODtablet
administration.
Adverse event review X X X X X X X X X
Concomitant
medication reviewX X X X X X X X X
Abbreviations : CRU = clinical research unit; ECG = electrocardiogram; D =Day; ED=early discontinuation; h =hour; M8 = metabolite 8; OD = oral 
disintegrating; P = predose; PK = pharmacokinetic(s).  
aThe Day  5 and Day 6 visits of a treatment period may occur at the same time as the Day -1 and Day  1 visits, respectively, of the subsequent treatment period. 
Therefore, assessments that occur on both visits will only be performed once. All results must be reviewed prior to dosing on Day 1 of each treatment period.  
The Day  6 visit of Treatment Period 3 will be considered the final visit.  
CONFIDENTIAL Protocol  H8H -MC-LAIA
122. Introduction
Lasmiditan (LY573144) has been developed by Eli Lilly  and Com pany (Lilly ), and approve d by 
the Food and Drug Administration (FDA), for the acute treatment of migraine with or without 
aura in adults. Full details of the preclinical and clinical safet y and tol erabili ty data are con tained 
in the Invest igator’s Brochure (IB).  
2.1. Study Rationale
Previous clinical studies of lasmidi tan ha veused an immediate -release (IR) tabl et formulation. 
Anoral-disintegrat ing(OD) tablet has been dev eloped to support pediatric devel opment and for 
more convenient administration in adults, e.g., for those who hav e difficul ty swall owing a tabl et.  
This study  is intended to determine the bioequivalence , safet y, and tol erabili tyof anewly
developed ODtablet of lasmidi tan compared to the current IR tablet. Informat ion on the 
acceptabilit y and palatabilit y of the OD tablet will also be collected during the study . 
2.2. Background
Lasmiditan is a low -molecular -weight agoni st of the 5-hydroxy tryptamine ( 5-HT)1Freceptor 
with a nonvascular and primarily  neural mechanism  of action. It has a high affinit yfor the 
human 5 -HT1Freceptor and a >440
-fold selectivit y for the human 5 -HT1Freceptor relat ive to the 
5-HT1Breceptor. Lasmiditan has high solubilit y and perm eabili ty.
Lasmiditan doses have been evaluated in healthy participant s or patients with migrain e across 
completed Phase 1, 2, and 3 clinical studies. Across these studies, single intravenous and single 
oral doses of l asmidi tan were administered over a range of 0.1 mg to 400 mg. Mult iple oral  doses 
of 200 mg or 400 mg were administered orally once da ily(QD) for 7days. Cum ulatively through 
14August 2018, approximately 4945 participant s have received lasmiditan. The most frequently 
reported lasmiditan adverse events ( AEs)in the 2 Phase 3 placebo -controlled studies, in which 
patients treated 1 migrai ne attack wi th oral lasmiditan (50, 100, or 200 mg) or placebo, were 
dizziness, paresthesia, somnolence, fat igue, and nausea, and the majorit y were mild or m oderate 
in severit y. Safety and tol erabili ty in heal thy participant s were similar up to the highest dose of 
400 m g administered as a single and mult iple (QD for 7 days) dose, with drowsiness, dizziness, 
and paresthesia being the most frequent ly reported AEs. The majorit y of these were mild in 
severit y, and none were severe
.
In previous studies, fo llowing single oral  dose administrati on of  lasmidi tan to heal thy 
participant s, lasmidi tan was absorbed wi th a median time of maximum observed drug 
concentration ( tmax)of 1.8 hours, and rapidly eliminated with a mean terminal half- life (t 1/2) of 
approximately  5.7 hours. Lasmiditan exposure increased in a dose-dependent manner that was 
considered to be approximately linear with dose over a clinical dose range of 50 to 20 0 mg. No 
accumulat ion of lasmiditan was previously  observed wi th repeated QDdosing of 200 or 400 mg. 
Lasmiditan undergoes extensive hepat ic and extrahepatic metabo lism with ketone reduction to 
inact ive metabo lite 8 (M8)as the major biotransformat ion path way.  
CONFIDENTIAL Protocol  H8H -MC-LAIA
132.3. Benefit/Risk Assessment
There i s no antici pated therapeuti c benefi t for the healt hy participant s.
A 100 -mg dose of lasmiditan will be used in the current study. Oral doses of l asmidi tan up to the 
highest single and mult iple oral dose given (400 mg) were well tolerated in healt hy partici pants, 
with no drug -related serious adverse events (SAEs) or withdrawals due to AEs as of 14 August 
2018. Lasmiditan caused no significant QT prolongation either at 100 or 400 mg, and no 
clinically significant changes in clinical laboratory data. Lasmiditan has been associated with a 
mean decrease in heart rate of 5 to 10 bpm compared to 2 to 5 bpm for placebo. Addit ionally , in 
non-elderly healt hy volunteers ,a mean increase in blood pressure of approximately 2 to 3 mmH g 
was observed 1 hour after dosing with 200 m glasmiditan . There were no addit ional findings on 
vital signs foll owing QD dosing for 7 day s. Overall, in previous healt hy volunteer studies ,these 
changes were well tolerated. Although central  nervous system d isorders were commo nly 
reported as AEs, especially at higher dose levels, they were generally mild or moderate in 
intensity.  
Participants shoul d avoi d driving or operating m achinery  for at least 8 hours following dosing 
with lasmidi tan. This ri sk is mit igated in the current study  as participants will be confined to the 
clinical research unit ( CRU ).
More detailed informat ion about the known and expected benefits and risks and reasonably 
expected AEs oflasmiditan may be found in the IB.
CONFIDENTIAL Protocol  H8H -MC-LAIA
154. Study Design
4.1. Overall Design
Study  H8H -MC-LAIA (LAIA) is a Phase 1, open -label, rando mized, single -dose, 3-way 
crossover study  in healthy participants. Approximately 48participants will be enrolled such that 
36participants , 6 per treatment sequence ,complete the study .
Screening
All participants will be screened within 28 days prior to enrollment. 
Treatment and Assessment Period
Eligible partici pants will take part in 3 separate dosing periods. In each period, p articipants will 
be admitted to the CRU on Day  
-1and remain resident in the CRU untildischarge on Day 6.At 
the discret ion of the invest igator, participants may remain resident in the CRU for the ent irety of 
the study , i.e., from admissi on to the CRU on Day  -1 of Period 1 until discharge from the CRU 
on Day  6 of Period 3, after all assessments have been compl eted. 
There will be a washout period of ≥5 days between the day of dosing in 1 period and the day of 
dosing in the subsequent period. Days 5 and 6 of Period 1 and 2 may  coincide with Days -1 
and1 of Period 2 and 3, respectively, provided the required was hout between lasmiditan doses is 
observed. 
On Day  1 of Period 1, p articipants will be equally randomized to receive a 100 -mg oral dose in 
1of 6 dosing sequences in each of 3 dosing periods as shown in Table LAIA. 1. 
Table LAIA. 1. Dosing Sequences for Protocol H8H -MC-LAIA
Sequence Period 1 Period 2 Period 3
1 IR (reference) OD without water (test) OD with water (test)
2 IR (reference) OD with water (test) OD without water (test)
3 OD without water (test) OD with water (test) IR (reference)
4 OD without water (test) IR (reference) OD with water (test)
5 OD with water (test) IR (reference) OD without water (test)
6 OD with water (test) OD without water (test) IR (reference)
Abbreviations: IR = immediate release; OD = oral disintegrating.
Pharmacokinet ic blood sampling and safet y assessments, including vital sign measurements,
physical examinat ions, clinical laboratory  tests, el ectrocardi ograms (ECGs), and AE recording 
will be performed according to the So A (Section 1.3).
Follow -up
Day 6 of Period 3 will  be consi dered the final visit of the study . 
CONFIDENTIAL Protocol  H8H -MC-LAIA
164.2. Scientific Rationale for Study Design
In order to minimize any potential period effect and to allow each participant to act as his/her 
own control, a rando mized, 3 -sequence, crossover design has been selected.
Based on the t1/2of lasmidi tanand its metabo lites, at least 5 day sbetween the day of dosing in 
1period and the day of dosing in the subsequent period is considered sufficient time for the 
study  drug to washout.  
Conducting the study  in healt hy participants mitigates the potential confounding effects of the
disease state and concomitant medications in partici pants wi th migraine. A popul ation of healthy 
participants isfrequent ly used in the assessment of the pharmacokinet ics (PK)of both sm all and 
large mole cules .
This study  will be open label as the study primary  endpoint PK m easures are obj ective rather
than subject ive.
4.3. Justification for Dose
An oral dose of 100mg lasmiditan is a clinically effect ivedose for the target populat ion, based 
on data obtained fro m previous completed studies. 
Previous studies in healthy participants have shown single doses of lasmiditan up to 400 mg are 
generally safe and well tolerated. 
4.4. End of Study Definition
A participant is considered to have co mpleted the study  if he/she has co mpleted all requi red 
phases of the study  including the last scheduled procedure shown in the SoA (Section 1.3).
The end o f the study  is defined as the date of the last vi sit of the l ast parti cipant in the study .
CONFIDENTIAL Protocol  H8H -MC-LAIA
175. Study Population
Eligibilit y of parti cipants for enrollment in the study  will be based o n the results of screening 
medical history , physical examinat ion, vital signs, clinical laboratory  tests ,and ECG . 
The nature of any condit ions present at the time of the physical examinat ion and any preexist ing 
condi tions will  be docum ented.
The inclusio n and exclusio n criteria used to determine eligibilit y shoul d be applied at screening 
only and at the discretion of the invest igator through predose Day  1 (Peri od 1 only )for safet y, 
not con tinuously  throughout the tri al.
Screening may occur up to 28 days prior to enrollment . Parti cipants who are not enrolled within 
28 days of screening may  undergo an addi tional medi cal assessment and/or clinical 
measurements to confirm their eligibilit y. In such instances, repeat the fo llowing screening tests 
and procedures : wei ght, vi tal signs, ECG, clinical laboratory  tests, and pregnancy  test (f emales 
only).  
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted
5.1. Inclusi on Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
Participant Characteristics
1. A re males or females from 18to 65years of age inclusive, at the time of signing the 
inform ed consent .
For contraception requirements of this protocol, see Appendix 4 ( Secti on 10.4).
2.Have a body  mass index of 19.0 to 35.0 kg/m 2, inclusive at the time o f screening .
3. A re overtly healt hy as determined by medical evaluation including :
medical history
physical examinat ion
laboratory  tests
ECG
vital signs .
4.Have clinical laboratory  test results within normal reference range for the populat ion or 
CRU, or results within acceptable deviat ions that are judged to be not clinically 
significant by  the invest igator.
5.Have venous access sufficient to allow for blood sampling as per the protocol.
Informed Consent
6.Capable of giving signed informed consent as described in Ap pendix 1 (Secti on 10.1),
which includes co mpliance wit h the requirements and restrictions listed in the informed 
consent form (ICF) and in this protocol .
CONFIDENTIAL Protocol  H8H -MC-LAIA
185.2. Exclusion Criteria
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Medical Conditions
1.Have k nown allergies to lasmiditan, related compounds ,or any  com ponents of the 
formulation of lasmiditan, or a history  of significant atopy .
2.Have a history  of clinically significant allergic reactions to medications or food products , 
at the discretion of the investigator .
3. H ave an abnormal blood pressure and/or pulse rate ,as determined by the invest igator .
4. H ave clinically  significant abnorm alities on ECG ,as determined by  investi gator .
5. H ave a history  or presence of cardio vascular, respiratory, renal, gastrointest inal, 
endocrine, hematological, or neurological disorders capable of significant ly altering the 
absorpti on, m etabo lism, or eliminat ion of drugs; of constituting a risk when taking the 
study  interventi ons; or of interfering wit h the interpretation of data. 
Note: Uncomplicated procedures such as appendectomy, splenectomy, and 
cholecystectomy are considered as acceptable ,at the discret ion of the investigator .
6. S how a history  of centr al nervous system  condi tions such as strokes, transient ischemic 
attacks, significant head trauma, seizures, central nervous system infect ions, migraine, 
brain surgery , or any  other neurol ogical condi tions that, in the opinio n of the invest igator, 
increase the risk of participat ing in the study .
7. H ave a history  or presence of neuropsy chiatri c disease (e.g., manic depressive illness, 
schizophrenia, depression) considered as clinically significant by  the investi gator .
Prior/Concomitant Therapy
8.Have used or are intending to use over -the-counter or prescription medicat ion, including 
dietary  supplements, within 14 days prior to dosing and unt il study  discharge (apart from 
occasi onal acetaminophen, horm onal contracepti on, or horm one-replacement therapy ).
Prior/Concurrent Clinical Study Experience
9.Are current ly enrolle din any other clinical study  involving a study intervention or any 
other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study .
10. H ave part icipated, within the past 30 days of admissio n, in a clinical study  involving any 
study  interventi on. If  the previ ous study  intervent ion has a long half -life, 5 half -lives or 
30 day s (whichever i s longer) shoul d have passed .
11. H ave previously co mpleted or withdrawn fr om this study  or any  other study  invest igating 
lasmiditan, and have previously received the investigat ional product .
Diagnostic assessments
12.Have posit ive findings on drug screening.
13.Show evidence of human immunodeficiency virus (HIV) and/or posit ive HIV an tibodies.
14.Show evidence of hepat itis Band/or have a positive hepat itis B surface ant igen testresul t 
at screening .
CONFIDENTIAL Protocol  H8H -MC-LAIA
1915.Show evidence of hepat itis C and/or have positive hepat itis C ant ibody test result at 
screening. 
Note: Participants with posit ive hepatit isC ant ibody due to prior resolved disease can be 
enrolled if a confirmatory negat ive hepatit is C RNA test is obtained.
16.Positive hepat itis C RNA test result at screening.
Note: Test is optional and participants with negat ive hepat itis C antibody test are not 
requi red to al so undergo hepatit is C RNA testing.
Other Exclusions
17.Have donated blood of more than 500 mL within the previous 2 months of screening.
18.Regularly use known drugs of abuse or have a past history  of drug abuse .
19.Have an average weekly alcoho lintake that exceeds 21 units per week (males) and 
14units per week (females ), or are unwilling to stop al coho l consumption fro m 24 hours 
prior to admissio nand whilst resident at the CRU. At all other times, participants must 
agree to consume no more tha n 3 units per day  (mal es) and 2 units per day  (females).
(1unit=12 oz. or 360 mL of beer; 5 oz. or 150 mL of wine; 1.5 oz. or 45 mL of dist illed 
spirits).
20.Smokemore than 10 ci garettes or e-cigarettes , or 3 cigars, or 3 pipes , per day  andare 
unable to refrain fro m smoking while resident in the CRU , incl uding the use of any  
nicotine -containing products (e.g., nicotine patches) .
21.Consume excessive amounts of coffee, tea, col a, or other caffeinated beverages per day , 
or are unwilling to stop caffeine consumpt ion 24 hours prior to admission and whi lst 
resident at the CRU . Excessive amount is defined as greater than 6 servings per day  
(1serving is approximately equivalent to 120 mg of caffeine). 
22.Are unable to comply  with the di etary  regimen of the CRU.
23.Are females who have a posit ive pregnancy test at screening or on admission to CRU 
(Day -1).
24. A refemales planning to become pregnant during the study  or wi thin 1 m onth of study  
completion.
25. Are females who a relactating .
26.Are invest igative site personnel direct ly affiliated with this study  and/or thei r immediate 
families . Immediate family is defined as a spouse, bio logical  or legal  guardian, child, or 
sibling.
27.Are Lilly  or Covance empl oyees.
28.In the opinion o f the invest igator or sponsor, are unsuitable for inclusio n in the study .
5.3. Lifestyle Considerations
Throughout the study , parti cipant s may undergo medical assessments and review of compliance 
with requi rements before continuing in the study .  
CONFIDENTIAL Protocol  H8H -MC-LAIA
205.3.1. Meals and Dietary Restrictions
During each confinement period, participants will consume only food and beverages that are 
provi ded to them  by the CRU staff. Standard meals (e.g., breakfast, lunch, dinner, and snack) 
will be provided to the participants while resident at the CRU.
Lasmiditan will be administered after an overnight fast of at least 8 hours. On Day  1 of each 
dosing period, participants will abstain fro m water at l east 1 hour before and after dosing (except 
for water given wit h the dose). Participants will remain fasting for approximately  4 hours 
postdose, at which time a meal will be served .
5.3.2. Caffeine, Alcohol, and Tobacco
Participants will abstain fro m ingest ing caffeine -or xanthine -containing products ( e.g., coffee, 
tea, cola drinks ,and chocolate) for 24 hours prior to admissio n and whist resident in the CRU .
Parti cipants will abstain from alcohol consumpt ion 24 hours prior to admission and while 
resident at the CRU. At all other times, participants must agree to consume no more than 3 units 
per day  for males or 2 units per day  for females .
Parti cipants who use tobacco products will be instructed that use of nicotine -containing products 
(including nicotine patches) will not be permitted while they are in the 
CRU.
5.3.3. Activity
Parti cipants will abstain from strenuous exercise for 48hours before each b lood collect ion for 
clinical laboratory  tests. Participant s may parti cipate i n light recreational act ivities during studies 
(e.g., watch ingtelevision, read ing).
5.4. Screen Failures
Screen failures are defined as participant s who consent to participate in the clinical study but are 
not subsequently enrolled in the study .
Individuals who do not meet the criteria for participation in this study  (screen failure) may notbe 
rescreened. Repeating o f laboratory  tests during the screening peri od or repeating screening 
assessments to com ply wit h the protocol -designated screening period does not const itute 
rescreening. 
CONFIDENTIAL Protocol  H8H -MC-LAIA
216. Study Intervention
Study  intervent ion is defined as an y invest igational intervent ion(s), m arketed product(s), 
placebo ,or medical device (s)intended to be administered to /used by a study  parti cipant 
according to the study  protocol .
6.1. Study Interventions Administered
This study  involves the comparison of a single 100- mg dose of lasmiditan OD tablet (test) versus 
the current IR tablet formulat ion (reference). Table LAIA.2shows the study  interventi ons to be 
administer ed.
Table LAIA. 2. Study Interventions Administered
Study intervention Lasmiditan Lasmiditan
Dosage formulation Immediate -Release Tablet Oral-Disintegrating Tablet
Unit dose strength/ dosage 
level100-mg tablet 100-mg tablet
Route of administration Oral Oral
Use Reference Test
Dosing instructions1 tablet taken on Day 1 of the treatment
period according to the randomized 
dosing sequence1 tablet taken on Day 1 of the treatment
period with or with outwater according to 
the randomized dosing sequence
Sourcing Provided centrally by the sponsor Provided centrally by the sponsor
Packaging and labellingStudy intervention will be provided in a 
blister . Each blister will be labeled per 
country requirementStudy intervention will be provided in a 
blister .Each blister will be labeled per 
country requirement
6.1.1. Administration Details
Parti cipants will be equally rando mized to 1of 6dosing sequences in each of 3 dosing periods as 
described in Section 4.1.
For each dosing period, parti cipants will receive a single oral dose on the morning of Day  1.  
IR tablet: Participants receiving the IR tablet formulat ion will swallow the tablet with 
240 mL of room -temperature water.  
OD tablet (without water): Immediately before dose administration participants 
receiving the OD tablet formulat ion without water will receive 20 mL of room -
temperature water to wet their palettes. Then using a dry  hand, parti cipants will place the 
OD tabl et on top of the tongue and keep it there until it disintegrates. A gent le pressure 
may be exerted on the tablet by  pressing the tongue agains t the roof of the m outh to 
facilitate disintegration of the tablet. The participants will then fully swallow the saliva 
containing both disintegrated and any un- disintegrated remaining part of the tablet.
OD tablet (with water): Immediately before dose adm inistrati on parti cipants receiving 
the OD tablet formulat ion withwater will receive 20 mL of room -temperature water to 
wet thei r palettes. Then using a dry  hand, parti cipants will place the OD tablet on top of 
the tongue and keep it there until it disinte grates. A gent le pressure may be exerted on the 
CONFIDENTIAL Protocol  H8H -MC-LAIA
22tablet by  pressing the tongue against the roof of the mouth to facilitate disintegrat ion of 
the tablet. Once the tablet has disintegrated, th e parti cipants will then drink 240mLof 
room -temperature water andswallow withthe saliva containing both disintegrated and 
any un -disintegrated remaining part of the tablet .
All doses will be administered in a sitting position and participants will not be allowed to lie 
supine for 2 hours after dosing, unless clinically indicated or for study  procedures.
6.2. Preparation/Handling/Storage/Accountability
1.The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all study  intervent ion received and any discrepancies are 
reported and resolved before use of the study  intervent ion.
2.Only participants enro lled in the study  may receive study  intervent ion and only 
authori zed si te staff may  supply  or administer study  intervent ion. All study  intervent ion 
must be stored in a secure , environmentally controlled, and mo nitored (m anual  or 
autom ated) area in accordance wit h the l abeled storage conditions with access limited to 
the invest igator and authorized site staff.
3.The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  interventi on accountabilit y, reconciliat ion, and record maintenance 
(i.
e., recei pt, reconciliat ion, and final disposit ion records).
4.Theinvest igator or designee will return all unused study interventions to Lilly or its 
designee at the end of the study . In som e cases, si tes m ay destroy  the m aterial if, during 
the CRU select ion, the evaluator has verified and documented that the site has 
appropriate facilit ies and written procedures to dispose of clinical mate rials.
6.3. Measures to Minimize Bias: Randomization and Blinding
This is an open -label study; potential bias will be reduced by central rando mizat ion.
On Day  1 of Treatment Peri od 1, participants will be assigned a unique number (randomizat ion 
number). The ran domizati on number encodes the participant’s assignment to 1of 6 treatment 
sequences , according to the randomizat ion schedule generated prior to the study  by the Stati stics 
Departm ent at Covance . Each parti cipant will be dispensed study  intervent ion, labeled wi th 
his/her unique rando mizat ion number, throughout the study .
6.4. Study Intervention Compliance
Participants are dosed at the site andthey will receive study  intervent ion directly from the 
investigator or designee, under medical supervisio n. The date an d time of each dose administered 
in the clinic will be recorded in the source documents and recorded in the electroni c case report 
form (eCRF ). The dose of study  intervent ion and study  parti cipant i dentificat ion will be 
confirmed at the time of dosing by a member of the study  site staff other than the person 
administering the study  interventi on. Study  site personnel  will examine each parti cipant’s m outh 
to ensure that the study  intervent ion was ingested.
CONFIDENTIAL Protocol  H8H -MC-LAIA
236.5. Concomitant Therapy
Parti cipants m ust abstain from  taking prescript ion or nonprescript ion drugs (including dietary
supplements) within 14 days pri or to dosing and until study  discharge , unless, in the opinio n of 
the invest igator and sponsor, the medication wil l not interfere with the study .
Acetaminophen , at doses of 3 g/24 hours , is permitted for use at the discret ion of the 
investigator for the treatment of headache etc. Contraceptive medicat ion is permitted as per the 
contraception requirements (Secti on 10.4) and hormo ne-replacement therapy  is also allowed. 
Other concomitant medicat ion may be considered on a case -by-case basis by the invest igator in 
consultation wit h the Lilly clinical pharmaco logist (CP)/clinical research physician ( CRP ), or 
designee .
6.6. Dose Modification
Dose m odificat ion is not permitted in t his study .
6.7. Intervention after the End of the Study
Not applicable. 
CONFIDENTIAL Protocol  H8H -MC-LAIA
247. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
Parti cipants discont inuing from study intervent ion prem aturely  for any  reason shoul d com plete 
AEand other fo llow-up/early  discontinuat ionprocedures as per the SoA (Section 1.3).
Parti cipants discont inuing from the study  prem aturely for any  reason m ust com plete AE and 
follow
-up/early  discontinuat ionprocedures as per the SoA (Section 1.3).
Discontinuati on of  specific sites or of the study  as a who le is described in Appendix 1 
(Secti on10.1.7 ).
7.1. Discontinuation of Study Intervention
Discontinuati on of  the study  drug for abnorm al liver tests should be considered by the 
investigator when a participant meets 1 of the fo llowing condit ions after consultation with the 
Lilly -designated m edical m onitor:
alanine aminotransferase (ALT) or aspartate amino transferase (AST) >5 × upper limit o f 
norm al (ULN)
ALT or AST >3 × ULN sustained for more than 2 weeks
ALT or AST >3 × ULN and total bilirubin level (TBL) >2 × ULN or internationa l 
norm alized rati o >1.5
ALT or AST >3 × ULN and the appearance o f fatigue, nausea, vo miting, right 
upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%) .
7.2. Participant Discontinuation/ Withdrawal from the Study
A participant may withdraw f rom the study :
at any  time at his/her own request 
at the request of his/her designee (for example, parents or legal guardian)
at the discretion of the invest igator for safet y, behavi oral, com pliance, or 
administrative reasons
if the participant beco mes p
regnant during the study
if enro llment in any other clinical study invo lving an invest igational product or 
enrollment in any other type o f medical research judged not to be scient ifically or 
medically co mpat ible with this study.
Discontinuati on is expect ed to be unco mmo n.
At the time of discont inuing from the study , if possible, an early discont inuat ion visit should be 
conducted, as shown in the S oA(Secti on 1.3). See SoA for data to be collected at the time of 
study  discont inuat ion and fo llow-up and for any  further eval uations that need to be completed .
The participant will be permanently discont inued both fro m the study  intervent ionand from  the 
study  at that time .
CONFIDENTIAL Protocol  H8H -MC-LAIA
25If the participant withdraws consent for disclos ure of  future inform ation, the s ponsor m ay retain 
and cont inue to use any data collected before such a withdrawal o f consent .If a participant
withdraws fro m the study , he/sh e may  request destructi on of  any sam ples taken and not tested ,
and the invest igator must document this in the site study records .
7.2.1. Discontinuation of Inadvertently Enrolled Participants
If the sponsor or invest igator ident ify a participant who did not meet enrollment criteria and was 
inadvertent ly enro lled, then the participant shoul d be discont inued fro m study  treatm ent unl ess 
there are extenuating circumstances that make it medically necessary for the participant to 
continue on study  treatm ent. If the investigator and the sponsor CRP agree it is medically 
appropriate to continue, the invest igator must obtain documented approval fro m the sponsor CRP 
to allow the inadvertently enrolled participant to continue in the study  with or wi thout treatm ent 
with invest igational product. Safet y follow-up is as outlined in Sect ion 1.3(SoA), Section 8.2
(Safet y Assessments) , and Secti on 8.3(Adverse Events and Serious Adverse Events) of the 
protocol .
7.3. Lost to Follow -up
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits a nd is unable to be contacted by  the study  site.Site personnel are expected to 
make diligent attempts to contact participants who fail to return for a scheduled visit or were 
otherwi se unable to be fo llowed up by the site.
CONFIDENTIAL Protocol  H8H -MC-LAIA
268. Study Assessments and Procedures
Study  procedures and their timing sare summarized in the SoA (Secti on 1.3).
Protocol waiver s or exem ptions are not allowed.
Immediate safet y concerns shoul d be discussed wit h the s ponsor immediately  upon occurrence or 
awareness to determine if the participant should cont inue or discont inue study  intervent ion.
Adherence to the study  design requi rements, including those specified in the S oA, is essent ial 
and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potenti al participant s 
meet all eligibilit y criteria. The invest igator will maintain a screening log to record details o f all 
participant s screened and to confirm eligibilit y or record reasons for sc reening failure, as 
applicable.
Appendix 2 (Secti on 10.2)lists the laborator y tests that will be performed for this study .
Appendix 2 (Section 10.2.1 ) provides a summary of the maximum number and vo lume of 
invasive samples, fo r all sampling, during the study.
Unless otherwise stated in subsect ions below, all samples collected for specified laboratory  tests 
will be destroy ed wi thin 60 days of receipt of confirmed test results. Certain samples may be 
retained for a longer period, if necessary , to com ply with applicable laws, regulat ions, or 
laboratory  certificati on standards.
Assessment collection time
The specificat ions in this protocol for the timings of safet y and sample co llection are given as 
targets to be achieved wit hin reasonable limits. Modificat ions may be made to the time po ints 
based upon emerging clinical informat ion. The scheduled t ime poin ts may be subject to minor 
alterati ons; however, the actual time must be correctly  recorded in the eCRF. Failure or being 
late (that is, outside stipulated time allowances) to perform procedures or obtain samples within 
the stipulated time allowances due t o legit imate clinical issues (for example, equipment technical 
probl ems, venous access difficult y) will not be considered protocol deviat ions. However, the 
CRU is required to notify the sponsor in writ ing using a file note.
8.1. Efficacy Assessments
Efficacy is not evaluated in this study .
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA (Section 1.3).
8.2.1. Physical Exam inations
Acomplete physical examinat ion will include, at a minimum, assessments of the cardiovascular, 
respiratory , gastrointestinal ,and neurol ogicalsystems. Height and weight will also be measured 
and recorded.
Invest igators should pay special attenti on to clinical signs related to previous illnesses.
CONFIDENTIAL Protocol  H8H -MC-LAIA
27Addit ional symptom -driven physical examinat ions may be performed at the discret ion of the 
investigator.
Any clinically  significant findings in a physical examinat ion shoul d be reported as AEs.
8.2.2. Vital Signs
For each participant , vital signs m easurements shoul d be conducted according to the S oA
(Secti on1.3).
Blood pressure and pulse rate should be measured after at least 5 minutes supine. For each 
individual participant , the same cuff size should be used throughout the study  for the 
measurements of blood pressure. The cuff should be attached to the participant ’s dominant arm.
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture -induced symptoms. Where orthostatic measurements are required, participants should be 
supine for at least 5 minutes and stand for atleast 2 minutes, but no longer than 3 minutes . If the 
participant feels unable to stand, supine vital signs only will be collected. 
Addit ional vital signs may be m easured during each dosing period if warranted and agreed upon 
between Lilly and the invest igator .
8.2.3. Electrocardiograms
For each participant, a single 12-lead digital ECG will be collected as outlined in the SoA 
(Secti on1.3)
.
Electrocardiograms must be recorded before collecting any blood samples. Participants must be 
supine for approximately  5 to 10 minutes before ECG collect ion and rem ain supine but awake 
during ECG collect ion. 
Electrocardiograms may be obtained at addit ional times, when deemed clinically necessary . All 
ECGs recorded should be stored at the invest igational site .
Electrocardiograms will be interpreted by  a qualified physician (the investigator or qualified 
designee) at the site as soon after the time of ECG c ollect ion as possible, and ideally while the 
participant is still present, to determine whether the participant meets entry  criteria at the rel evant 
visits and for immediate participant management, should any  clinically rel evant findings be 
ident ified. 
Ifa clinically significant finding is ident ified (including, but not limited to, changes in 
QT/corrected QT interval from baseline) after enrollment, the invest igator will determine if the 
participant can continue in the study . The invest igator, or qualifie d designee, i s responsible for 
determining if any change in part icipant management is needed, and must document his/her 
review of the ECG printed at the time of co llection. Any new clinically relevant finding should 
be reported as an AE.
8.2.4. Clinical Safety Laboratory Assessments
See Appendix 2 (Secti on 10.2)for the list of clinical laboratory  tests to be performed and the 
SoA for the timing and frequenc y.
The l aboratory  reports m ust be filed wit h the source documents. 
CONFIDENTIAL Protocol  H8H -MC-LAIA
28The invest igator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study  in the AE section of the eCRF. 
All laborat ory tests wi th values considered clinically  significantly abnorm al during parti cipat ion 
in the study  shoul d be repeated until the values return to normal or baseline or are no longer 
considered clinically significant by  the investi gator or Lilly CP.
If suc h values do not return to normal/baseline wit hin a peri od of  time judged reasonable 
by the investigator, the etio logy should be identified and the sponsor notified.
All protocol -requi red laboratory  assessments, as defined in Appendix 2 (Sect ion 10.2), 
must be conducted in accordance wit h the laboratory  manual and the SoA (Section 1.3).
If laboratory  values fro m non-protocol -specified laboratory  assessments perform ed at the 
institution’s l ocal laboratory  requi re a change in parti cipant m anagement or are 
considered clinically significant by  the investi gator (e .g., SAE or AE), then the resul ts 
must be recorded in the eCRF.
8.2.5. Safety Monitoring
The Lilly CPor CRP will monitor safet y data throughout the course of the study .
Lilly will review SAEs wit hin time frames mandated by company procedures (Section 8.3.1 ). 
The Lilly CP or CRP will periodically  review :
trends in safety  data
laboratory  analy tes 
AEs.
When appropriate, the Lilly CP or CRP will consult with the funct ionally  independent Gl obal 
Patient Safet y medical physician or clinical research scient ist.
8.2.5.1. Hepatic Safety
Close hepatic monitoring
Laboratory  tests ( Appendix 6, Section 10.6), including ALT, AST, alkaline phosp hatase ( ALP ), 
and TBL, shoul d be repeated , with the addi tion of  direct bilirubin, gamma -glutamyl transferase, 
and creat ine kinase, within 48 to 72 hours to confirm the abnormalit y and to determine if it is 
increasing or decreasing, if 1 or more of these condit ions occur:
If a participant with baseline results of ... develops the following elevations:
ALT or AST <1.5 ×ULN ALT or AST ≥3×ULN
ALP <1.5 ×ULN ALP ≥2×ULN
TBL <1.5 × ULNTBL ≥2×ULN (except for participants with Gilbert’s 
syndrome)
ALT or AST ≥1.5 ×ULN ALT or AST ≥2×baseline
ALP ≥1.5 ×ULN ALP ≥2×baseline

CONFIDENTIAL Protocol  H8H -MC-LAIA
29TBL ≥1.5 ×ULNTBL ≥2×baseline (except for participants with Gilbert’s 
syndrome)
If the abnormalit y persists or worsens, clinical and laboratory  monitoring and evaluat ion for 
possible causes of abnormal liver tests should be init iated by  the invest igator in consultat ion with 
the Lilly -designated CP. At a minimum, this evaluation should include physical examinat ion and 
a thorough m edical history , including symptom s, recent illnesses (for example, heart failure, 
systemic infect ion, hypotensio n, or seizures), recent travel, history  of concomi tant m edicati ons 
(includin g over -the-counter), herbal and dietary  suppl ements, history  of alcohol  drinking and 
other substance abuse.
Initially, m onitoring of  symptoms and hepat ic biochemical tests should be done at a frequency o f 
1 to 3 times weekly , based on the parti cipant’s cli nical condi tion and hepat ic biochemical tests.  
Subsequently, the frequency  of monitoring m ay be l owered to once every  1 to 2 weeks, if the 
participant’s clinical condit ion and l aboratory results stabilize. Monitoring of ALT, AST, ALP, 
and TBL should continue unt il levels norm alize or return to approximate baseline levels.
Comprehensive hepatic evaluation  
A co mprehensive evaluat ion shoul d be perform ed to search for possible causes of liv er injury  if 
one or m ore of these condit ions occur:
If a participant with baseline results of... develops the following elevations:
ALT or AST <1.5 ×ULN ALT or AST ≥3×ULN with hepatic signs/symptoms*, or
ALT or AST ≥5×ULN
ALP <1.5 ×ULN ALP ≥3×ULN
TBL <1.5 × ULN TBL ≥2×ULN (except for participants with Gilbert’s syndrome)
ALT or AST ≥1.5 ×ULN ALT or AST ≥2×baseline with hepatic signs/symptoms*, or
ALT or AST ≥3×baseline
ALP ≥1.5 ×ULN ALP ≥2×baseline
TBL ≥1.5 ×ULN TBL ≥1.5 ×baseline (except for participants with Gilbert’s 
syndrome) 
* Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, and/or 
eosinophilia >5%.
At a minimum, this evaluat ion should include physical examinat ion and a thorough medical 
history , as outlined above, as well as tests for prothrombin t ime-internat ional normalized rat io; 
tests for viral hepatit is A, B, C, or E; tests for autoimmune hepat itis; and an abdo minal imaging 
study  (for example, ul trasound or com puted tom ography  scan).  
Based on the participant’s history  and ini tial resul ts, further testing should be considered in 
consultation wit h the Lilly -designated CP, including tests for hepat itis D virus, cytomegalo virus, 
Epstein -Barr virus, acetaminophen levels, acetaminophen protein adducts, urine toxicology  
screen, Wilson’s disease, blood alcoho l levels, urinary  ethyl glucuronide, and serum 
phosphatidylethanol. Based on the circumstances an d the investi gator’s assessment of the 
participant’s clinical condit ion, the invest igator should consider referring the participant for a 
hepatol ogist or gastroenterologist consultation, magnet ic resonance cho langiopancreatography , 
endoscopi c retrograde ch olangi opancreatography , cardi ac echocardi ogram , or a liver biopsy.  
CONFIDENTIAL Protocol  H8H -MC-LAIA
30Additional hepatic data collection in study participants who have abnormal liver test 
results during the study
Addit ional safet y data collect ion in hepat ic safet y eCRF shoul d be perform edin study  
participants who meet 1 or more of the fo llowing condi tions:  
Elevat ion of serum ALT to ≥5× ULN on 2 or more consecutive blood tests (if baseline 
ALT <1.5× ULN)
oIn parti cipants wi th baseline ALT ≥1.5 × ULN, the thresho ld is ALT ≥3× 
baseline on 2 or more consecutive tests
Elevated serum TBL to ≥2× ULN (if baseline TBL <1.5 × ULN) (except for cases of 
known Gilbert’s syndro me)
oIn parti cipants wi th baseline TBL ≥1.5 × ULN, the thresho ld should be TBL ≥2× 
baseline
Elevat ion of serum ALP to ≥2× ULN on 2 or more consecutive blood tests (if baseline 
ALP <1.5 × ULN)
oIn parti cipants wi th baseline ALP ≥1.5 × ULN, the thresho ld is ALP ≥2× baseline 
on 2 or more consecutive blood tests
Hepati c event consi dered to be anSAE
Discontinuati on of  study  drug due to a hepatic event.
Note : The interval between the 2 consecut ive blood tests should be at least 2 day s.
8.3. Adverse Events and Serious Adverse Events
Adverse event swill be reported by  the parti cipant (or, when appropri ate, by  a caregiver, 
surrogate, or the participant's legally authorized representative).
The invest igator and any qualified designees are responsible for detecting, documenting, and 
recording events th at meet the definit ion of an AE or SAE and remain responsible for fo llowing 
up AEs that are serious, considered related to the study  intervent ion or study  procedures, or that 
caused the participant to discont inue the study  intervent ionor study  (see Secti on 7).
Invest igators are responsible for monitoring the safety of participants who have entered this 
study  and f or alerting Lilly  or its designee to a ny event that seems unusual, even if this event 
may be considered an unant icipated benefit to the participant.
The invest igator is responsible for the appropriate medical care of participants during the study.
8.3.1. Time Period and Frequency for Collecting AE an d SAE Information
All AEs and SAEs will be collecte d from the signing of the ICF until participati on in study  has 
ended .
Adverse events that begin before the start of study  intervent ion but after signing of the ICF will 
berecorded on the Adverse Event eCRF.
Although all AEs after signing the ICF are recorded by the site in the eCRF, SAE reporti ng to 
sponsor begins after the participant has signed the ICF and has received study drug. However, if 
CONFIDENTIAL Protocol  H8H -MC-LAIA
31an SAE occurs after signing the ICF, but prior to receiving lasmiditan , it needs to be reported 
ONLY if it is considered reasonably possibly related to study  procedures.
All SAEs will be recorded and reported to the s ponsor or designee immediately and under no 
circumstance shoul d this exceed 24 hours, as indicated in Appendix 3 (Secti on 10.3). The 
investigator will submit any
 updated SAE data to the sponsor within 24 hours of i t being 
available.
Invest igators are not obligated to actively seek AE sor SAE safter concl usion of the study  
participat ion. However, if the invest igator learns of any SAE, including a death, at any t ime after 
a participant has been discharged from the study , and he/she considers the eve nt to be reasonably 
related to the study  intervent ion or study  parti cipati on, the invest igator must prompt ly notify  the 
sponsor .
8.3.2. Method of Detecting AEs and SAEs
The m ethod of recording, evaluat ing, and assessing causalit y of AE and SAE and the procedures 
for com pleting and transmitt ing SAE reports are provided in Appendix 3 (Secti on10.3).
Care will be taken not to introduce bias when detecting AEs and /or SAEs. Open -ended and 
non-leading verbal quest ioning of the participant is the preferred method to inquire about AE
occurrences .
8.3.3. Follow -up of AEs and SAEs
After the init ial AE/SAE report, the investigator is required to proactively fo llow each participa nt 
at subsequent visits/contacts. All SAEs will be fo llowed until reso lution, stabilizat ion, the event 
is otherwi se explained, or the participant is lost to fo llow-up (as defined in Sect ion7.3). Further 
inform ation on fo llow-up procedures is provi dedin Appendix 10.3.
8.3.4. Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by the invest igator to the sponsor of a nSAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y of parti cipants and the safet y of a study  
intervent ion under clinical investigat ion are m et.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and other 
regul atory  agencies about the safet y of a study  intervent ion under clinical investigation. The 
sponsor will co mply wi th country -specific regul atory  requi rements relating to safet y reporti ng to 
the regulatory  authori ty, Inst itutional Review Boards (IRB s)/Independent Ethics Co mmittees 
(IEC s), and invest igators.
An invest igator who receives an invest igator safety report describing a n SAE or other specific 
safet y informat ion (e.g., summary or list ing of SAEs) from the sponsor will review and then file 
it along wi th theIBand will notify the IRB/IEC , if appropri ate according to l ocal requi rements.
8.3.5. Pregnancy
Details o f all pregnancies in female participants and female partners of male participants will be 
collected after the start of study  intervent ion and unt il study  end.
CONFIDENTIAL Protocol  H8H -MC-LAIA
32If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours of learning 
of the pregnancy  and should fo llow the procedures outlined in Appendix 4 (Secti on10.4).
Abnorm al pregnancy outcom es (e.g., spontaneous abortion, feta l death, stillbirth, congenital 
anomalies, ectopi c pregnancy ) are considered SAEs.
Pregnancy (maternal or paternal exposure to study  intervent ion) does not m eet the definit ion of 
an AE. However, to fulfill regulatory  requi rements, any
 pregnancy  should be r eported following 
the SAE process described in Appendix 3 (Secti on10.3) to collect data on the outcome for both 
mother and fetus.
8.3.6. Product Complaints
A product complaint is any written, electronic, or oral communicat ion that alleges deficiencies 
related to the id entity, quali ty, durabili ty, reliabili ty, safety, effect iveness ,or performance of a 
trial intervent ion.
Sponsor collects product complaints on investigational products and drug delivery systems used 
in clinical studies in order to ensure the safet y of study parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
Parti cipants will be instructed to contact the invest igator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product so that the situa tion can be assessed.
Note: AEs/SAE sthat are associated with a product complaint will also fo llow the processes 
outlined in Sect ion 8.3.3 and Appendix 3 (Secti on10.3) of the protocol .
8.3.6.1. Time Period for Detecting Product Complaints
Product complaints that resul t in an AEwill be detected , docum ented, and reported to the 
sponsor during all periods of the study in wh ich the drug is used.
If the inv estigator l earns of any product com plaint at any  time after a participant has been 
discharged from  the study , and such incident is considered rea sonably related to a drug provided 
for the study , the invest igator will pro mptly notify the sponsor.
8.3.6.2. Prompt Reporting of Product Complaints to Sponsor
Product complaints will be reported to the sponsor within 24 hours after the invest igator beco mes 
aware of the com plaint .
The Product Com plaint Form  will be sent to the sponsor by email.Ifemail  is unavailable, then
faxshoul d be ut ilized .
8.3.6.3. Follow -up of Product Complaints
Follow-up applies to all participants, including those who discont inue study  intervent ion.
The invest igator is responsible for ensuring that follow -up includes any supplemental 
investigat ions as indicated to elucidate the nature and/or causalit y of the product complaint .
New or updated informat ion will be recorded on the originally co mpleted form with all changes 
signed and dated by the invest igator and submitted to the sponsor .
CONFIDENTIAL Protocol  H8H -MC-LAIA
338.4. Treatment of Overdose
For thi s study , any dose of lasmiditan greater than 100mgwithin a 24 -hour time period will be 
considered an overdose.
There i s no specific antidote for lasmiditan. 
In the event of an overdose , the invest igator/treating physician shoul d:
1.Contact the Lilly CP immediately.
2.Closely  monitor the parti cipant for any  AE/SAE and laboratory  abnorm alities unt il study  
intervent ion can no longer be detected sy stemically  (at least2days).
3.Docum ent the quanti ty of the excess dose as well as the duration of the overdose in the 
eCRF.
Decisio ns regarding dose interruptions will be made by the invest igator in consultat ion with the 
Lilly CP based on the clinical evaluat ion of the participant.
8.5. Pharmacokinetics
Venous blood samples of approximately 2 mL will be collected for measurement of plasma
concentrations of lasmiditan and M8, as specified in the SoA (Section 1.3).
A maximum of 3samples m ay be collected at additional t ime po ints during the study  if 
warranted and agreed upon between the invest igator and the sponsor.
Instructi ons for the collect ion and handling of bio logical samples will be provided by the 
sponsor. The actual date and time (24-hour clock time) of each sample will be recorded.
8.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by the sponsor and stored at a facilit y 
designated by  the sponsor.
Concentrations of lasmidi tanand M8 will be assayed using a validated liquid chro matography  
with tandem  mass spectrom etry method.
Bioanaly tical samples collected to m easure study  intervent ion concentrations will be retained for 
a maximum  of 1year following last parti cipant vi sit for the study .
8.6. Pharmacodynamics
Pharmacodynamic parameters a re not evaluated in this study .
8.7. Genetics
A blood sample for DNA i solation will be collected fro m participants. 
See Appendix 5 (Secti on10.5) for information regarding genetic research .
8.8. Biomarkers
Biomarkers are not eval uated in thi s study .
CONFIDENTIAL Protocol  H8H -MC-LAIA
348.9. Immunogenicity Assessments
Immunogenicit y isnot evaluated in this study .
8.10. Health Economic s
This sect ion is not applicable for this study . 
8.11. Product Acceptability and Palatability Assessments
The participant will be asked to provide responses to questions designed to assess the 
acceptabilit y and palatabilit y of the OD tablet when administered with and without water. The 
questionnaire will assess the participant ’s experience relat ing to the taste , smell, mouthfeel , 
aftertaste , and the approximate disintegrat iontime ofthe OD tablet in the oral cavit y.
The quest ionnaire will be co mpleted by  the participant immediately after administration of the 
OD tabl et both with and without water. 
CONFIDENTIAL Protocol  H8H -MC-LAIA
359. Statistical Considera tions
9.1. Statistical Hypotheses
Bioequivalence of the OD tabl et wi thout water versus the current IR tablet will be established if 
the 90% confidence interval (CI) of the ratio of geometric least square means for area under the 
concentration versus t ime curve (AUC ) from time zero to infinit y (AUC [(0-∞]) , AUC fro m time 
zero to time t, where t is the last time po int with a measurable concentration (AUC[0 -
tlast]),and 
maximum observed drug concentration ( Cmax)is within the testing boundaries of 0.8 and 1.25.
9.2. Sample Size Determination
A total o f36 participants are requi redcomplete the study  to establish equivalence between the 
OD tabl et formulation without water and the current IR tablet, based on the PK parameters 
measured.
Given the 6×3design this woul d mean at least 6 participants would be randomly assigned to each 
of the 6 dosing sequences. The calculated total number of participants assumes 90% power for 
the two one -sided test (TOST) for equivalence with a significance level of 5%, analogous to a 
90% CI. Further, t his is based on
:
anominally assigned true m ean rati o of 1.05
acoefficient of variat ion for Cmaxof 24.1%
ratio testi ng boundaries of 0.8 and 1.25.
Assuming that 25% of participants will drop out or fail to provide full study data, approximately 
48 participants shoul d be enrolled to ensure that 36 participants , 6 per treatment sequence, will 
complete the study .
9.3. Populations for Analyses
The following popul ations are defined:
Population Description
Enrolled All participants rando mly a ssigned to study  intervent ion.
Safety All enrolled participants who received at least 1 dose of study  
intervent ion. Parti cipants will be analyzed according to the 
intervent ion they actually  received .
Pharmacokinet ic Analysis All enrolled participants who received at least 1 dose of study  
intervent ion and have evaluable PK data.
9.3.1. Study Participant Disposition
A detailed description o f participant disposi tion will be provided at the end of the study .
9.3.2. Study Participant Characteristics
The participants ’ age, sex, wei ght, hei ght, body mass index , race, and other dem ographic 
characterist ics will be recorded and summarized using descript ive statist ics.
CONFIDENTIAL Protocol  H8H -MC-LAIA
369.4. Statistical Analyses
Statistical analysis o f this study  will be the responsibilit y ofthe sponsor or its desi gnee.
Any change to the data analysis methods described in the protocol will require an amendment 
only if it changes a princi pal feature of the protocol. Any  other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
in the statist ical analysis plan ( SAP)and the clinical study  report. Addi tional expl oratory  
analyses o f the data will be conducted as deemed appropriate.
The SAP will be finalized prior to the first participant visit an d it will  include a m ore technical 
and detailed descript ion of the statistical analyses described in this sect ion. This sect ion is a 
summary of the planned statist ical analyses of the most important endpoints including primar y 
and key  secondary endpoints.
9.4.1. General Considerations
Data list ings will be provided for all data that are databased. Data list ings will be provided for all 
participants up to the point of withdrawal, with any  parti cipants excl uded f rom the rel evant 
popul ation highlighted.
Summary  statistics and stati stical analysis will only be presented for data where detailed in the 
SAP. Summary statist ics and statist ical analyses will generally only be performed for 
participants included in the relevant analysis populat ion. For the calculat ion of summary  
statist ics and statist ical analysis, unrounded data will be used.
9.4.2. Pharmacokinetic Analyses
9.4.2.1. Pharmacokinetic Parameter Estimation
Pharmacokinet ic parameter estimates for lasmiditan and M8, based on plasma concentrations,
will be calculated by standard noncompartmental methods of analysis and summari zed using 
descript ive statistics .
The primary PK param eters f or analysis will be C max,AUC (0-∞) , and AUC from time zero to 
time t, where t is the last time po int with a measurab le concentration (AUC[0 -
tlast])of
lasmiditan .  
Other noncompartmental parameters, such as half -life, apparent clearance, and apparent volume 
of distribut ion may be reported.
9.4.2.2. Pharmacokinetic Statistical Inference
Log-transfor med AUC(0 -∞), AUC(0 -tlast),and C maxof lasmidi tan will be evaluated in a linear 
mixed -effects m odel with fixed effects for period, sequence , and treatm entand a random effect 
for parti cipant within sequence .
All valid PK data will be included, whether or not the participants completed all  3 peri ods.
Estimates of geometric least square mean ratios together with the corresponding 90% CI swill be 
derived for the comparisons o f AUC(0 -∞), AUC(0 -tlast),and C maxas fo llows:
Primary endpo int: lasmidi tanOD tablet without water (test) versus lasmiditan IR tabl et
CONFIDENTIAL Protocol  H8H -MC-LAIA
37Secondary  endpoint: l asmidi tan OD tabl et wi th water (test) versus lasmiditan IR tablet.
The 2 l asmidi tan formulations will be considered bioequivalent if the 90% CIs of the ratio of 
geom etric least square means fall s completelywithin 0.80 to 1.25.
Values of  tmaxwill be analyzed non -parametrically  using the Wilco xon signed rank test.
Estimates of the median difference between test and reference formulat ions based on the 
observed medians, 90% CIs ,and the p- value from the Wilcoxon test will be calculated .
Addit ional PK analyses may be conducted if deemed appropriate.
9.4.3. Safety Analyses
9.4.3.1. Clinical Evaluation of Safety
All study  intervent ionand protocol  procedure AEs will be listed, and ,if the frequency o f events 
allows, safet y data will be summarized using descript ive methodol ogy.
The incidence of symptoms for each treatment will be presented by  severi ty and by associ ation 
with study  intervent ionas perceived by the invest igator. Sympto ms reported to occur prior to 
enrollment will be dist inguished from those reported as new or increased in severit y during the 
study . Each symptom  will be classified by  the m ost sui table term  from the m edical regulatory  
dictionary.
The number of study  intervention-related SAEs will be reported.
9.4.3.2. Statistical Evaluation of Safety
Safety param eters that will be assessed include safety  laboratory  parameters and vital signs. The 
param eters will  be listed and summarized using standard descriptive statist ics. Addit ional 
analysis will be performed if warranted upon review of the data.
9.4.4. Product Acceptability and Palatability Analyses
Responses fro m the product acceptabilit y and palatabilit y quest ionnaire will be summarized 
categori cally (frequency and percentage).
9.5. Interim Analyses 
No interim analyses are planned for this study . If an unplanned interim analysis is deemed 
necessary  for reasons other than a safet y concern, the protocol must be amended.
9.6. Data Monitoring Committee (DMC)
Not applicable to this study . 
CONFIDENTIAL Protocol  H8H -MC-LAIA
3810. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medical Sciences 
(CIOMS) International Ethical Guidelines
Applicable Internat ional Council for Harmonisation (ICH) Good Clinical Practice (GCP) 
Guidelines
Applicable laws and regulations .
The protocol, protocol amendments, ICF, IB, and other relevant documents (e .g., adverti sements) 
must be submitted to an IRB /IEC by the invest igator and reviewed and approved by the I RB/IEC
before the study  is init iated.
Any amendments to the protocol will require IRB /IEC approval before implementation of 
changes made to the study  design, except for changes necessary  to eliminate an immediate 
hazard to study  parti cipants.
The invest igator will  be responsible for the following:
Provi ding wri tten summaries of the status of the study  to the IRB /IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB /IEC
Notifying the IRB of SAEs or other si gnificant safety  findings as required by IRB /IEC
procedures
Provi ding oversight of the conduct of the study  at the site and adherence to requirements 
of 21 Code of Federal Regulat ions (CFR )
, ICH guidelines, the IRB/IEC, European 
regul ation 536/2014 for clinical studies (if applicable), and all other applicable local 
regul ations.
Invest igator sites are compensated for participat ion in the study as detailed in the clinical trial
agreem ent.
10.1.2. Informed Consent Process
The invest igator or his/her r epresentative will explain the nature of the study , including the risks 
and benefits, to the parti cipant or his/her l egally  authori zed representati veand answer all
questions regarding the study .
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary. Partici pants or thei r legally  
authori zed representative will be required to sign a statement of informed consent that meets the 
requi rements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portabilit y and 
Accountabilit y Act (HIPA A) requi rements, where applicable, and the I RB/IEC or study  center.
CONFIDENTIAL Protocol  H8H -MC-LAIA
39The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained before 
the participant was enter ed in the study  and the date the written consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF.
Parti cipants m ust be re -consented to the most current versio n of the ICF during th eir 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the participant or the partici pant’s legally  authori zed 
representati veand is kept on file.
10.1.3. Data Protection
Parti cipants will be assigned a unique ident ifier by the sponsor. Any part icipant records ,datasets
or tissue samples that are transferred to the sponsor will contain the identif ier only; participant 
names or any  information which would make the participant ident ifiable will not be transferred.
The parti cipant must be inform ed that hi s/her personal  study -related data will  be used by  the 
sponsor in accordance wit h local data protec tion law. The l evel of disclosure m ust also b e 
explained to the participant who will be required to give consent for their data to be used as 
described in the informed consent .
The parti cipant must be inform ed that hi s/her m edical  records m ay be examined by Clinical 
Qualit y Assurance auditors or other authorized personnel appo inted by  the sponsor, by  
appropriate IRB /IEC members, and by inspectors from regulatory  authori ties.
The sponsor has processes in place to ensure data protection, informat ion securit y and data 
integrity. These processes include appropriate contingency plan(s) for appropriate and timely 
response in the event of a data securit y breach.
10.1.4. Dissemination of Clinical Study Data
Communication of Suspended or Terminated Dosing
If a decisio n is taken to suspend or terminate dosing in the trial due to safet y findings, this 
decisio n will be communicated by Lilly to all investigators (for example, by phone and/or email) 
as soon as possible. It will be a requirement that investigators respond upon receipt to confirm 
that they  understand the communication and have taken the appropriate action prior to further 
dosing any participants with study  intervent ion. Any invest igator not responding will be 
followed up by  Lilly personnel pri or to any  further planned dosing. If a dose is planned 
imminent ly, Lilly personnel will immediately, and continually, use all efforts to reach 
investigators until contact is made and instructions verifi ed.
Reports
The sponsor will disclose a summary o f study  information, including tabular study results, on 
publicly  available websites where required by  local law or regul ation. 
CONFIDENTIAL Protocol  H8H -MC-LAIA
40Data 
The sponsor does not proactively  share data from  Phase 1 clinical trials. Requests for access to 
Phase 1 clinical trial data are evaluated on a case -by-case basis taking into considerat ion the 
abilit y to anonymize the data and the nature of the data collected.
10.1.5. Data Quality Assurance
All participant data relat ing to the s tudy will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (e .g., laboratory  data). The invest igator is 
responsible for verifying that data entries are accurate and correct by  physically  or electronicall y 
signing the CRF.
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the CRF.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and regulatory  
agency  inspect ions and pr ovide di rect a ccess to source data documents.
Moni toring details describing strategy  (e.
g., risk -based init iatives in operations and qualit y such 
as Risk Management and Mit igation Strategies and Analyt ical Risk-Based Monitoring), methods, 
responsibilit ies and requirements, including handling of nonco mpliance issues and monitoring 
techniques are provided in the Moni toring Pl an.
The sponsor or designee is responsible for the data management of this study  includin g qualit y 
checking o f the data.
The sponsor ass umes accountabilit y for acti ons delegated to other individuals (e
.g., Contract 
Research Organizat ions).
Study  monitors will perform  ongoing source data verification to confirm that data entered into 
the CRF by  authori zed si te personnel  are accurate, com plete, and verifiable fro m source 
docum ents; that the safet y and ri ghts of  parti cipants are being protected; and that the study  is 
being conducted in accordance with the current ly approved protocol and any other study 
agreem ents, ICH GCP, and all applicable r egulatory requirements.
Records and documents, including signed ICFs, pertaining to the conduct of this study  must be 
retained by the invest igator for the time period outlined in the Clinical Trial Agreement (CTA)
unless local regulat ions or inst itutional policies requi re a l onger retenti on peri od. No records m ay 
be destroy ed during the retention period without the written approval of the sponsor. No records 
may be transferred to another location or party  without wri tten notificat ion to the sponsor .
In addi tion, the sponsor or its representatives will periodically  check a sample of the participant
data recorded against source documents at the study site. The study  may be audi ted by  
sponsor or 
its representatives, and/or regulatory  agencies at any  time. Investigators will be given notice 
before an audit occurs.
Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
CONFIDENTIAL Protocol  H8H -MC-LAIA
41An electronic data capture (EDC) system will be used in this study  for the collect ion of CRF 
data. The invest igator maintains a separate source for the data entered by  the invest igator or 
designee into the sponsor -provided EDC syst em. The invest igator is responsible for the 
ident ificat ion of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  signing the CRF .
Data collected via the sponsor- provided data capture system will be stored at a thirdparty .The 
investigator will have cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem .Prior to decommissio ning, the invest igator will receive an archival 
copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system and reports will be provided to the investigator for review 
and retention. Data will subsequent ly be transferred fro m the central  vendor to the sponsor data 
warehouse.
Data from co mplaint forms submitted to sponsor will be encoded and stored in the global 
product complaint management sy stem .
10.1.6. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the invest igator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed fro m source documents 
must be consistent with the source documents or the di screpancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on the 
study . Also, current m edical records must be available.
Definit ion of what constitutes source data can be found in Section 10.1.5 .
10.1.7. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruit ment of 
participants.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  time 
for any  reason at the sol e discret ion of the sponsor. Study  sites will  be cl osed upon study  
completion. A study  site is considered cl osed when all req uired docum ents and study  supplies 
have been co llected and a study -site closure visi t has been perform ed.
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the inte nded terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include but are 
not limited to:
Failure of the invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the spo nsor's procedures, or GCP guidelines
Inadequate recruit ment of parti cipants by  the investi gator
Discontinuati on of  further study  intervent ion developm ent.
CONFIDENTIAL Protocol  H8H -MC-LAIA
42If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investi gators, the IECs/IRBs, the regulatory  authorit ies, and any contract research organizat ion(s) 
used in the study  of the reason for terminat ion or suspensio n, as specified by the applicable 
regul atory  requi rements. The investigator shall prompt ly inform  the participant and assure s
appropriate participant therapy  and/or foll ow-up.
10.1.8. Publication Policy
In accordance with the sponsor’s publication po licy, the results of this study  will be submitted 
for publicat ion by a peer -reviewed journal if the results are deemed t o be of significant medical 
importance.
CONFIDENTIAL Protocol  H8H -MC-LAIA
4310.2. Appendix 2: Clinical Laboratory Tests
The tests detailed below will be performe d by the local laboratory .
Protocol -specific requirements for inclusio n or exclusio n of participants are detailed in Sect ion 5
of the protocol.
Addit ional tests may be performed at any  time during the study  as determined necessary  by the 
investigator or requir ed by  local regulati ons.
Pregnancy testing will be conducted as detailed in the SoA (Section 1.3).
Invest igators must document their review of each laboratory  safety  report.
CONFIDENTIAL Protocol  H8H -MC-LAIA
44Clinical Laboratory Tests
Hematology Clinical Chemistry
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Bicarbonate
Mean cell volume Chloride
Mean cell hemoglobin Calcium
Mean cell hemoglobin concentration Phospho rus/Phosphate
Leukocytes (WBC) Glucose (fasting )
Platelets Blood urea nitrogen
Differential WBC ( absolute counts and % )of: Creatinine
Neutrophils Uric acid
Lymphocy tes Total protein
Monocytes Albumin
Eosinophils Total bilirubin a
Basophil s Alkaline phosphatase
Aspartate aminotransferase
Urinaly sis Alanine aminotransferase
Specific gravity
pH Ethanol testing b
Protein Urine drug screen b
Glucose Hepatitis B surface antigen c
Ketones Hepatitis C antibody c,d
Bilirubin HIV c
Urobilinogen
Blood Serum p regnancy  test (all females )c
Nitrite Urine pregnancy test (all females) e
Microscopic examination of sediment f FSH (postmenopausal females only) c
Abbreviations : FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus ;RBC = red blood cells; 
WBC = white blood cells.
Note: Results of these assays will be validated by the local laboratory at the time of testing. Additional tests may be 
performed or aut o-calculated by the laboratory as part of its standard panel that cannot be removed. Some of the 
above parameters are calculated from measured values. Omission of calculated values will not be considered as a 
protocol violation.
aDirect and indirect bilir ubin will be analyzed if total bilirubin is elevated.
bPerformed at screening and admission to the clinical research unit ( CRU ;Day -1).
cPerformed at screening only .
dParticipants with a positive hepatitis C antibody test result can have a confirmatory hepatitis C RNA test.
ePerformed for all females on admission to CRU (Day -1). A positive urine test will be confirmed with a serum 
pregnancy test. 
fTest only if dipstick result is abnormal .
CONFIDENTIAL Protocol  H8H -MC-LAIA
4510.2.1. Blood Sampling Summary
This table summarizes the approxima te number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es, and bioanaly tical assays) during the study . 
Protocol H8H -MC -LAIA Sampling Summary
PurposeBlood Volume per 
Sample (mL)Number of Blood 
SamplesTotal Volume 
(mL)
Screening tests a 19.5 1 19.5
Clinical laboratory tests a 12.5 6 75
Pharmacokinetics 2 51b102
Pharmacogenetics 10 1 10
Total 206.5
Total for clinical purposes 210
aAdditional samples may be drawn if needed for safety purposes . 
bIncludes additional 3 samples, if required .
CONFIDENTIAL Protocol  H8H -MC-LAIA
50Initial notificati on via telephone does not replace the need for the invest igator to 
complete and sign the SAE report within the designated reporting time frames.
Contacts for SAE reporting can be found in SAE Report.
CONFIDENTIAL Protocol  H8H -MC-LAIA
5110.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information
10.4.1. Definitions
Females of Childbearing Potential
A female is considered fertile fo llowing menarche and until beco ming postmenopausal unless 
perm anent ly sterile (see below).
If fertilit y is unclear (e .g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study  intervent ion, additional eval uation shoul d be considered.
Females NOT of Childbearing Potential 
Females in the fo llowing categori es are consi dered not of childbearing potential :
1. I nfert ile due to surgical sterilization
Docum ented hysterectomy
Docum ented bilateral  oophorectomy
Docum ent bilateral  tubal  ligation 
2. P ermanent infertil itydue to an alternate medica l cause other than the above, (e.g., mullerian 
agenesis .)
Note: Documentation can come fro m the site personnel’s review of the participant’s medical 
records, medical examinat ion, or m edical history  interview.
3.Postmenopausal  female defined as either:
a wom an at l east 40 y ears of age with an intact uterus, not on hormone ther apy, who has 
cessat ion of menses for at least 12 months without an alternative medical cause, AND a 
follicle -stimulat ing horm one >40 m IU/L
a wom an 55 y ears or ol der not on horm one therapy , who has had at least 12 months of 
spontaneous amenorrhea
a woman at least 55 y ears of age with a diagnosis of menopause prior to starting 
horm one-replacement therapy .
10.4.2. Contraception Guidance
10.4.2.1. Female Participants
All females must test negative for pregnancy  prior to ini tiation of treatment as indicated by  a 
negat ive serum pregnancy  test at the screening visit followed by  a negat ive urine pregnancy test 
within 24 hours pri or to exposure. A posit ive urine test will be confirmed with a serum  
pregnancy test.
Female participants not of childbearing potenti al are not required to adhere to contraceptive 
requi rements.
Female participants of childbearing potential must agree to use either 1 highly effect ive method 
of contracepti on (<1% failure rate) , or a combinat ion of 2 effect ive methods of contraception, see 
Secti on 10.4.3 , during the study and until 30 days after the last dose of study medicat ion. 
CONFIDENTIAL Protocol  H8H -MC-LAIA
5210.4.2.2. Male Participants
Male parti cipants are not required to adhere to contraceptive requirements.
10.4.3. Contraception Method s
Abstinence
Parti cipants who are abstinent (if this is complete abst inence, as their preferred and usual 
lifest yle) must agree to remain abst inent without sexual relat ionships with the opposite sex.
Same -sex relationships
Parti cipants who are in a same -sex relationship (as part of their preferred and usual lifest yle) 
must agree to stay  in a same -sex rel ationship without sexual relationships with the opposite sex. 
Parti cipants who are in exclusively  same -sex relationships as their preferred and usual lifest yle 
are not required to use contraception.
Highly effective and effective contraception methods
Highly effective methods of contraception (less than 1% failure rate)
Combined oral contraceptive pill and 
mini-pillIntrauterine device (such as Mirena ®and ParaGard ®)
NuvaRing ® Contraceptive patch –ONLY women less than 198 pounds (90 kg)
Implantable contraceptives Vasectomy –for partners of female participants
Injectable contraceptives (such as 
Depo -Provera ®)Fallopian tube implants (Essure ®) if confirmed by 
hysterosalpingogram
Total abstinence
Effective methods of contraception (use 2 forms combined except where noted)
Male condom with spermicide a Cervical sponge
Female condom with spermicide a Cervical cap with spermicide
Diaphragm with spermicide
aMale and female condoms should not be used in combination.
Unacceptable contraception methods
Unacceptable methods of contraception include
periodic abst inence, such as
ocalendar
oovulation
osymptothermal
opost-ovulation methods
declaration of a bstinence just for the duration of the study
withdrawal .
CONFIDENTIAL Protocol  H8H -MC-LAIA
5310.4.4. Collection of Pregnancy Information
Male participants wi th partners who become pregnant
The invest igator will attempt to collect pregnancy informat ion on any male participant’s 
female partner who becomes pregnant while the male participant is in this study. This 
applies only to male participants who receive lasmiditan.
After obtaining the necessary  signed informed consent from the pregnant female partner 
directly, the invest igator will record pregn ancy information on the appropriate form and 
submit it to the sponsor within 24 hours of learning of the partner’s pregnancy . The 
female partner will also be fo llowed to determine the outcome of the pregnancy. 
Inform ation on the status of the mother and ch ild will  be forwarded to the sponsor. 
Generally, the fo llow-up will be no l onger than 6 to 8 weeks fo llowing the estimated 
delivery  date. Any  terminat ion of the pregnancy will be reported including fetal status 
(presence or absence of ano malies) andindica tion for the procedure. 
Female Participants who become pregnant
The invest igator will co llect pregnancy information on any female participant who 
beco mes pregnant while participat ing in this study .The init ial informat ion will be 
recorded on the appropria te form and submitted to the sponsor within 24hours of 
learning of a participant's pregnancy. 
The parti cipant will be fo llowed to determine the outcome of the pregnancy . The 
investigator will co llect fo llow-up inform ation on the participant and the neona te and the 
inform ation will be forwarded to the sponsor. Generally, fo llow-up will not be requi red 
for longer than 6 to 8 weeks bey ond the estimated delivery  date. Any  terminat ion of 
pregnancy will be reported, including fetal status (presence or absence o f anomalies) or 
indicat ion for the procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complicat ion or el ective terminat ion of a pregnancy  for medical  reasons will be reported 
as an AE or SAE. 
A spontaneous abortion (occu rring at <2 0weeks gestational age) or still birth (occurring 
at ≥20 weeks gestational age) is always considered to be an SAE and will be reported as 
such. 
Any post -study pregnancy -related SAE consi dered reasonably related to the study  
intervent ion by the investigator will be reported to the sponsor as described in 
Secti on8.3.4 . While the invest igator is not obligated to actively seek this informat ion in 
former study  parti cipants, he or she may  learn of an SAE through sponta neous reporting.
Any female part icipant who becomes pregnant while participat ing in the study  will 
discontinue study  interventi on.If the participant is discontinue d from the study  
intervent ion, follow the standard di scontinuat ion process and continue directly to the 
follow-up phase. The fo llow-up on the pregnancy  outcome shoul d continue independent 
of intervent ion or study  discontinuation.   
CONFIDENTIAL Protocol  H8H -MC-LAIA
5410.5. Appendix 5: Genetics
Use/Analysis of DNA
Genet ic variat ion may impact a participant’s response to study  intervent ion, suscept ibilit y to, and 
severit y and progressi on of  disease. Vari able response to study  intervent ion may be due to 
genet ic determinants that impact drug absorpt ion, distribut ion, metabo lism, and excretion; 
mechanism o f action of  the drug; di sease et io
logy; and/or m olecular subt ype of the disease being 
treated. Therefore, where local regulat ions and IRB/IEC allow , a blood sample will be co llected 
for DNA analysis from consenting part icipants.
DNA samples will be used for research related to lasmiditan ormigraine and related diseases. 
They  may also be used to develop tests/assays including diagnost ic tests related to lasmidi tan
and/or intervent ions of this drug cla ss and migraine . Genetic research may consist of the analysis 
of one or m ore candi date genes or the analysis of genet ic markers throughout the genome or 
analysis of the ent ire genom e (as appropri ate).
The samples may  be analyzed as part of a mult i-study  assessment of genetic factors involved in 
the response to lasmidi tanor study  intervent ions of this class to understand study disease or 
related condi tions.
The results of genet ic analyses may be reported in the clinical study  report or in a separate study  
summary.
The sponsor will store the DNA samples in a secure storage space with adequate measures to 
protect confident iality.
The samples will be retained while research on lasmidi tancontinues but no longer than 15years 
or other period as per local require ments.
CONFIDENTIAL Protocol  H8H -MC-LAIA
5510.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments
See Secti on 8.2.5.1 for guidance on appropri ate test sel ection.
The Lilly -designated central laboratory must complete the analysis of all selected testing except 
for microbi ology testing.
Local  testing m ay be performed in addit ion to central testing when necessary for immediate 
participant m anagement.
Results will be reported if a validated test or calculation is available.
Hematology Clinical Chemistry
Hemoglobin Total bilirubin
Hematocrit Direct bilirubin
Erythrocy tes (RBCs -red blood cells) Alkaline phosphatase (ALP)
Leukocytes (WBCs -white blood cells) Alanine aminotransferase (ALT)
Differential: Aspartate aminotransferase (AST)
    Neutrophils, segmented Gamma -glutamyl transferase (GGT)
    Lymphocytes Creatine kinase (CK)
    MonocytesOther Chemistry
    Basophils Acetaminophen
    Eosinophils Acetaminophen protein adducts
Platelets Alkaline phosphatase isoenzymes
Cell morphology (RBC and WBC) Ceruloplasmin
CoagulationCopper
Ethyl alcohol (EtOH)
Prothrombin time, internatio nal no rmalized ratio (INR )
(PT-INR)Haptoglobin
SerologyImmunoglobulin IgA (quantitative)
Hepatitis A virus (HAV) testing: Immunoglobulin IgG (quantitative)
    HAV total antibody Immunoglobulin IgM (quantitative)
    HAV IgM antibody Phosphatidylethanol (PEth)
Hepatis B virus (HBV) testing:Urine Chemistry
    Hepatitis B surface antigen (HBsAg) Drug screen
    Hepatitis B surface antibody (anti -HBs) Ethyl glucuronide (EtG)
    Hepatitis B core total antibody (anti -HBc)Other Serology
    Hepatitis B core IgM antibody Anti- nuclear antibody (ANA)
    Hepatitis B core IgG antibody Anti-smooth muscle antibody (ASMA) a
CONFIDENTIAL Protocol  H8H -MC-LAIA
56    HBV DNA d Anti- actin antibody b
Hepati tis C virus (HCV) testing: Epstein -Barr virus (EBV) testing:
    HCV antibody     EBV antibody
    HCV RNA d     EBV DNA d
Hepatitis D virus (HDV) testing: Cytomegalovirus (CMV) testing:
    HDV antibody     CMV antibody
Hepatitis E virus (HEV) testing:     CMV DNA d
    HEV IgG antibody Herpes simplex virus (HSV) testing:
    HEV IgM antibody     HSV (Type 1 and 2) antibody 
    HEV RNA d     HSV (Type 1 and 2) DNA d
Microbiology c Liver kidney microsomal type 1 (LKM -1) antibody
Culture:
    Blood
    Urine
aNot required if anti -actin antibody is tested.
bNot required if anti -smooth muscle antibody (ASMA) is tested.
cAssay ed ONLY by investigator -designated local laboratory; no central testing available.
dReflex/confirmation dependent on regulatory requirements, testing availability, or both.
CONFIDENTIAL Protocol  H8H -MC-LAIA
5710.7. Appendix 7: Abbreviations
Term Definition
5-HT 5-hydroxy tryptamine
AE adverse event
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under the concentration versus time curve
AUC(0 -∞) area under the concentration versus time curve from time zero to infinity
AUC(0 -tlast) area under the concentration versus time curve from time zero to time t, where t is the 
last time point with a measurable concentration
CFR Code of Federal Regulations
CI confidence interval
Cmax maximum observed dru g concentration
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CP clinical pharmacologist
CRF case report form
CRP clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
CRU clinical research unit
ECG electrocardiogram
eCRF electronic case report form
enroll The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
CONFIDENTIAL Protocol  H8H -MC-LAIA
58GCP good clinical practice
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IEC Independent Ethics Committee
informed consent A process by which a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to p articipate. Informed consent is 
documented by means of a written, signed and dated informed consent form .
investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including p roducts already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
IR immediate -release
IRB Institutio nal Review Board
M8 metabolite 8
OD oral-disintegrating 
participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a control .
PK pharmacokinetic (s)
QD once daily
SAE serious adverse event
SAP statistical analysis plan
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SoA Schedule of Activities
t1/2 terminal half -life
TBL total bilirubin
tmax time of maximum obs erved drug concentration
ULN upper limit of normal
CONFIDENTIAL Protocol  H8H -MC-LAIA
5911. References
None ci ted. 
Leo Document ID = b68f9a2b-3e5d-41e9-8785-c9b7a20d5bee
Approver: 
Approval Date & Time: 04-Sep-2020 16:04:48 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 08-Sep-2020 12:00:20 GMT
Signature meaning: Approved
PPD
PPD